Taking a right first-time approach to optimize end-to-end viral vector manufacturing
On demand

Taking a right first-time approach to optimize end-to-end viral vector manufacturing

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Taking a right first-time approach to optimize end-to-end viral vector manufacturing

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

There is continued demand for viral vector manufacturing as the number of clinical trials, approved products, and investments remains in growth mode. Unfortunately, a lack of standardized processes and equipment can make processes time and cost prohibitive, which is delaying innovation.

Designing quality and scalability into processes from the start can help to streamline process economics. Planning for how a process will scale from discovery into commercial phase should include the products and services needed, as well as how regulatory compliance will tighten into commercial production. Working with supportive and reliable product and service partners can help to alleviate many time and cost burdens and support fast tract options.

Join experts from upstream solutions provider, Polyplus and contract manufacturing and development organization, Exothera, next month for a discussion around the importance of focusing on future capacity requirements and capabilities from the start, whilst also bearing patient safety and patient access well in mind.

Attend this webinar to learn more about:

  • Bioprocess economics, scalability, and regulatory compliance
  • Securing your manufacturing through in-house or outsourcing strategies
  • Collaboration and innovation to treat more patients
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera

Hanna has made her whole career in the gene therapy field. Over the years she has been in several directors’ positions leading research and development at FKD Therapies, Finvector and Kuopio Center for Gene and Cell Therapy. Her research interest has focused on gene therapy and translational development, including early stage analyticals and the development of scalable, robust manufacturing processes operating under current regulatory guidelines. Her PhD was in Molecular Medicine, obtained from the University of Kuopio. She followed up her PhD with post doc work at the University of California San Diego UCSD, CA, USA, and the University of Eastern Finland, Kuopio, Finland. She has several patents related to vector manufacturing.

Julien Depollier
Julien Depollier
Director, Strategic Partnership at

Julien has a Ph.D. in Biochemistry and Cellular Biology from University of Montpellier II (France, 2004). With 15+ year experience in Life Science industry and 10+ years with Polyplus transfection®, mainly as Business Director Americas from 2013 to 2020. Since 2021, Julien has evolved to a more Strategic role in the company to develop alternative sales strategy and Business Partners across key Life Science market segments (Cell & Gene Therapy and others).